2024 ASCO | 肺癌重点研究题目速览！

非小细胞肺癌

摘要号：LBA 4

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

根治性放化疗（CRT）后使用奥希替尼（osi）治疗不可切除的Ⅲ期（stg）EGFR突变（EGFRm） NSCLC患者（pts）：Ⅲ期LAURA研究的主要结果

Presenter：Suresh S. Ramalingam

摘要号：8004 O

Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.

12个月或6个月辅助埃克替尼 vs. 辅助化疗后观察EGFR突变Ⅱ-ⅢA期非小细胞肺癌 （ICTAN，GASTO1002）：一项随机Ⅲ期试验

Presenter：王思愚 教授（中山大学肿瘤防治中心）

摘要号：LBA 8007

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

根据淋巴结状态分析的围手术期纳武利尤单抗（NIVO）治疗Ⅲ期可切除NSCLC患者（pts）的临床结局：来自Ⅲ期CheckMate 77T研究的结果

Presenter：Tina Cascone

摘要号：8008 O

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

一项评估新辅助化疗联合纳武利尤单抗和同步放化疗后使用纳武利尤单抗巩固治疗局部晚期非小细胞肺癌的Ⅱ期随机试验（GASTO-1091）

Presenter：刘慧 教授（中山大学肿瘤防治中心）

摘要号：LBA 8010

Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.

新辅助纳武利尤单抗（NIVO）+化疗（chemo）vs. 化疗治疗可切除NSCLC患者（pts）：CheckMate 816研究的4年更新结果

Presenter：Jonathan Spicer

摘要号：LBA 8035

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

IMpower010：辅助阿替利珠单抗 vs. 最佳支持治疗用于切除的ⅠB-ⅢA期非小细胞肺癌 （NSCLC） 的Ⅲ期研究进行≥5年随访后的最终无病生存期（DFS）和第二次总生存期（OS）期中结果

Presenter：Heather A. Wakelee

摘要号：LBA 8500

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

戈沙妥珠单抗（SG） vs. 多西他赛（doc）治疗既往接受过铂类（PT）化疗（chemo）和PD(L)-1抑制剂（IO）治疗的转移性非小细胞肺癌（mNSCLC）患者（pts）：Ⅲ期EVOKE-01研究的主要结果

Presenter：Luis G. Paz-Ares

摘要号：8502 O

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

来自Ⅱ期OptiTROP-Lung01研究的芦康沙妥珠单抗（SKB264/MK-2870）联合KL-A167（抗PD-L1）一线治疗晚期NSCLC患者

Presenter：方文峰 教授（中山大学肿瘤防治中心）

摘要号：LBA 8503

Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

劳拉替尼 vs. 克唑替尼治疗ALK+晚期非小细胞肺癌初治患者：CROWN研究的5年无进展生存期和安全性

Presenter：Benjamin J. Solomon

摘要号：8504 O

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.

埃万妥单抗联合拉泽替尼 vs. 奥希替尼一线治疗具有高危疾病生物标志物的EGFR突变晚期非小细胞肺癌（NSCLC）：来自Ⅲ期MARIPOSA研究的二次分析

Presenter：Enriqueta Felip

摘要号：LBA 8505

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

皮下注射 vs. 静脉注射埃万妥单抗，均联合拉泽替尼治疗难治性EGFR突变晚期非小细胞肺癌（NSCLC）：全球Ⅲ期随机对照PALOMA-3试验的主要结果，包括总生存期（OS）

Presenter：Natasha B. Leighl

摘要号：8506 O

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).

NRG-LU002：全身维持治疗 vs. 局部巩固治疗（LCT）联合全身维持治疗局限转移性非小细胞肺癌（NSCLC）的随机Ⅱ/Ⅲ期试验

Presenter：Puneeth Iyengar

摘要号：8508 O

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

ivonescimab联合化疗治疗接受EGFR TKI治疗进展的EGFR突变非鳞状非小细胞肺癌患者（HARMONi-A）：一项随机、双盲、多中心、Ⅲ期试验

Presenter：张力 教授（中山大学肿瘤防治中心）

摘要号：LBA 8509

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

KRYSTAL-12：阿达格拉西布 vs. 多西他赛治疗既往经治的具有KRAS G12C突变晚期/转移性非小细胞肺癌（NSCLC）患者的Ⅲ期研究

Presenter：Tony S. K. Mok

摘要号：LBA 8511

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

KROCUS：fulzerasib（GFH925）联合西妥昔单抗治疗既往未经治疗的晚期KRAS G12C突变NSCLC患者的疗效和安全性的Ⅱ期研究

Presenter：Vanesa Gregorc

摘要号：8512 CS

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

索托拉西布联合卡铂和培美曲塞治疗KRAS G12C突变晚期NSCLC：来自国际CodeBreaK 101试验的最新分析

Presenter：Bob T. Li

摘要号：8513 RO

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.

舒沃替尼治疗经铂类治疗且EGFR 20号外显子插入突变非小细胞肺癌的多国关键性研究：WU-KONG1研究的初步分析

Presenter：James Chih-Hsin Yang

摘要号：8516 RO

Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.

埃万妥单抗联合拉泽替尼治疗非典型EGFR突变的晚期非小细胞肺癌（NSCLC）：来自CHRYSALIS-2的结果

Presenter：Byoung Chul Cho

摘要号：8519 RO

Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.

劳拉替尼治疗TKI初治晚期ROS1阳性非小细胞肺癌：一项多中心、开放标签、单臂、Ⅱ期试验

Presenter：Beung Chul AHN

摘要号：8520 RO

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

taletrectinib在晚期或转移性ROS1+非小细胞肺癌患者中的疗效和安全性：Ⅱ期TRUST-I研究

Presenter：李玮 教授（同济大学附属上海市肺科医院）

摘要号：8606 P

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

埃万妥单抗联合化疗 vs. 化疗作为EGFR 20号外显子插入突变晚期非小细胞肺癌（NSCLC）的一线治疗：PAPILLON研究中国亚组分析

Presenter：唐可京 教授（中山大学附属第一医院）

摘要号：LBA 8612

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

皮下注射埃万妥单抗和拉泽替尼作为EGFR突变晚期非小细胞肺癌（NSCLC）患者的一线治疗：Ⅱ期PALOMA-2研究结果

Presenter：Sun Min Lim

小细胞肺癌

摘要号：LBA 5

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

ADRIATIC：度伐利尤单抗（D）作为局限期小细胞肺癌（LS-SCLC）患者（pts）的巩固治疗 (tx) 

Presenter：David R. Spigel

摘要号：8001 O

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

BEAT-SC：贝伐珠单抗或安慰剂联合阿替利珠单抗和铂为基础化疗治疗广泛期小细胞肺癌 （ES-SCLC）患者的随机III期研究

Presenter：Yuichiro Ohe

摘要号：8014 RO

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

adebrelimab联合化疗和序贯胸腔放疗作为广泛期小细胞肺癌一线治疗的总生存期

Presenter：陈大卫 教授（山东第一医科大学附属肿瘤医院）

摘要号：8015 RO

DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.

DeLLphi-301：tarlatamab治疗小细胞肺癌（SCLC）的Ⅱ期试验——根据脑转移状态进行的疗效和安全性分析

Presenter：Anne-Marie C. Dingemans

摘要号：8095 P

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

抗PD-L1治疗联合化疗治疗广泛期小细胞肺癌的Ⅲ期临床试验结果

Presenter：陆舜 教授（上海交通大学附属胸科医院）

摘要号：8100 P

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.

斯鲁利单抗 vs. 安慰剂联合化疗作为广泛期小细胞肺癌的一线治疗：国际Ⅲ期ASTRUM-005研究的扩展随访结果和患者报告结局

Presenter：程颖 教授（吉林省肿瘤医院）